상위피인용논문
- 조회654
ExoCoBio
Dae Hyun Ha1,†, Hyun-keun Kim1,†, Joon Lee2, Hyuck Hoon Kwon3, Gyeong-Hun Park4, Steve Hoseong Yang5, Jae Yoon Jung6, Hosung Choi7, Jun Ho Lee1, Sumi Sung1, Yong Weon Yi1,* and Byong Seung Cho1,*
1ExoCoBio Exosome Institute (EEI), ExoCoBio Inc., Seoul 08594, Korea
2School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Korea
3Oaro Dermatology Clinic, Seoul 13620, Korea
4Department of Dermatology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwasweong-si, Gyeonggi-do 18450, Korea
5Guam Dermatology Institute, Tamuning, GU 96913, USA
6Oaro Dermatology Clinic, Seoul 01695, Korea
7Piena Clinic, Seoul 06120, Korea
*Authors to whom correspondence should be addressed.
†These authors contributed equally to this article.
Abstract
Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. With their unique nucleic acids, proteins, and lipids cargo compositions that reflect the characteristics of producer cells, exosomes can be utilized as cell-free therapeutics. Among exosomes derived from various cellular origins, mesenchymal stem cell-derived exosomes (MSC-exosomes) have gained great attention due to their immunomodulatory and regenerative functions. Indeed, many studies have shown anti-inflammatory, anti-aging and wound healing effects of MSC-exosomes in various in vitro and in vivo models. In addition, recent advances in the field of exosome biology have enabled development of specific guidelines and quality control methods, which will ultimately lead to clinical application of exosomes. This review highlights recent studies that investigate therapeutic potential of MSC-exosomes and relevant mode of actions for skin diseases, as well as quality control measures required for development of exosome-derived therapeutics.
논문정보
- Review Paper
- 2020년 05월 (BRIC 등록일 2022-01-26)
- 국내(교신)+국외 연구진
- 60회 이상 인용된 논문
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
